Drug updates and approvals: 2018 in review.

Cortney Mospan Geoffrey Mospan Emily Byland William Blake Whitaker Linda Xiong Jordan Dunlap Katherine Canupp

Nurse Pract

Cortney Mospan is an assistant professor of pharmacy at Wingate University, Levine College of Health Sciences, Wingate, N.C. Geoffrey Mospan is an assistant professor of pharmacy at Wingate University, Levine College of Health Sciences, Wingate, N.C. Emily Byland is a PharmD candidate at Wingate University, School of Pharmacy, Wingate, N.C. William Blake Whitaker is a PharmD candidate at Wingate University, School of Pharmacy, Hendersonville, N.C. Linda Xiong is a PharmD candidate at Wingate University, School of Pharmacy, Wingate, N.C. Jordan Dunlap is a PharmD candidate at Wingate University, School of Pharmacy, Wingate, N.C. Katherine Canupp is a PharmD candidate at Wingate University, School of Pharmacy, Wingate, N.C.

Published: December 2018

In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).

Download full-text PDF	Source
http://dx.doi.org/10.1097/01.NPR.0000547548.63764.6b	DOI Listing

Publication Analysis

Top Keywords

drug updates

updates approvals

approvals 2018

2018 review

review 2018

2018 fda

fda approved

approved drugs

drugs primary

primary care

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!